Viatris Emerging Markets Segment — Selling, general and administration decreased by 15.1% to $71.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.3%, from $74.30M to $71.10M. Over 3 years (FY 2022 to FY 2025), Emerging Markets Segment — Selling, general and administration shows relatively stable performance with a -3.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Lower expenses relative to revenue indicate better operational efficiency, whereas rising costs may reflect aggressive expansion or increased regulatory compliance burdens.
This represents the operating expenses incurred to support the sales, marketing, and administrative functions of the eme...
Standard segment-level SG&A disclosure used to compare regional operating discipline across the pharmaceutical industry.
vtrs_segment_emerging_markets_segment_selling_general_and_administration| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $85.78M | $85.78M | $85.78M | $85.78M | $88.70M | $88.70M | $88.70M | $88.70M | $84.00M | $78.00M | $78.10M | $69.80M | $74.30M | $78.40M | $73.60M | $83.70M | $71.10M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +3.4% | +0.0% | +0.0% | +0.0% | -5.3% | -7.1% | +0.1% | -10.6% | +6.4% | +5.5% | -6.1% | +13.7% | -15.1% |
| YoY Change | — | — | — | — | +3.4% | +3.4% | +3.4% | +3.4% | -5.3% | -12.1% | -12.0% | -21.3% | -11.5% | +0.5% | -5.8% | +19.9% | -4.3% |